Amongst type 2 anti-inflammatory components, IL-33, whose function might be reduced in AD due to increased soluble ST2 receptor decoy levels, when administered to transgenic Aβ AD mice, promotes Aβ microglial clearance, reducing soluble Aβ and amyloid plaque pathology (Fu et al., 2016). The gene discussed is IL33; the disease is Alzheimer disease.